C2 Therapeutics Announces 15th Patient Enrollment in its Clinical Trial

//C2 Therapeutics Announces 15th Patient Enrollment in its Clinical Trial

C2 Therapeutics, a privately held company founded to address the limitations of current Barrett’s Esophagus (BE) treatment options, today announced that it enrolled the 15th patient in its Cryoballoon Focal Ablation System international study. Additionally, 10 patients have reached the 2-month follow-up period.

Click here for full release.

2017-05-16T21:29:58+00:00